Harmony Biosciences Holdings (HRMY) Net Margin (2020 - 2026)
Harmony Biosciences Holdings (HRMY) posted Net Margin of 15.08% for Q1 2026, down 43.66% sequentially from 26.77% in Q4 2025, and down 958.0% YoY from 1.76% in Q1 2025.
Harmony Biosciences Holdings (HRMY) Net Margin (2020 - 2026) Analysis & Trends
Harmony Biosciences Holdings has reported Net Margin for 7 years, with the latest figure at 15.08% in Q1 2026.
- Quarterly Net Margin fell 958.0% year-over-year to 15.08% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 20.95% (up 45.0% YoY) and the FY2025 annual result came in at 23.2%, up 284.0% from the prior year.
- Net Margin slipped to 15.08% in Q1 2026 per HRMY's latest filing, from 26.77% in the prior quarter.
- Over five years, Net Margin peaked at 75.03% in Q3 2022 and troughed at 6.71% in Q2 2024.
- A 5-year average of 25.8% and a median of 24.66% in 2025 frame the typical range for Net Margin.
- The sharpest annual moves came in 2022 and 2023: Net Margin jumped 8695 bps in 2022, then tumbled 5103 bps in 2023.
- Over 5 years, Net Margin stood at 37.81% in 2022, then slumped by 58 bps to 15.8% in 2023, then jumped by 56 bps to 24.58% in 2024, then climbed by 9 bps to 26.77% in 2025, then slumped by 44 bps to 15.08% in 2026.
- According to Business Quant data, Net Margin over the past three periods registered 15.08%, 26.77%, and 21.24% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 32.99% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 30.23% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 30.33% |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.90% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 30.98% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 12.09% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 12.74% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -3.12% |
| 10 | Harmony Biosciences Holdings | 2.22 Bn | 1.41 Bn | 198.08 Mn | 28.20% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 28.20% |
| Mar 31, 2026 | 15.08% |
| Dec 31, 2025 | 26.77% |
| Sep 30, 2025 | 21.24% |
| Jun 30, 2025 | 19.84% |
| Mar 31, 2025 | 24.66% |
| Dec 31, 2024 | 24.58% |
| Sep 30, 2024 | 24.78% |
| Jun 30, 2024 | 6.71% |
| Mar 31, 2024 | 24.79% |
| Dec 31, 2023 | 15.80% |
| Sep 30, 2023 | 24.00% |
| Jun 30, 2023 | 25.56% |
| Mar 31, 2023 | 24.75% |
| Dec 31, 2022 | 37.81% |
| Sep 30, 2022 | 75.03% |
| Jun 30, 2022 | 21.99% |
| Mar 31, 2022 | 25.18% |
| Dec 31, 2021 | 24.90% |
| Sep 30, 2021 | -11.92% |